Considering Insulin Secretory Capacity as Measured by a Fasting C-Peptide/Glucose Ratio in Selecting Glucose-Lowering Medications

Abstract

Type 2 diabetes mellitus is a heterogeneous disease. Recently introduced new subclassifications promise more efficacious, tailored treatments which could complement current guidelines. In the differentiation of the new diabetes subphenotypes, assessment of insulin secretion is one of the essential components. Based on a large number of insulin secretion measurements, we propose fasting C-peptide/glucose ratio (CGR) as an adequate and practicable estimate of insulin secretion. CGR discriminates insulin deficiency from insulin hypersecretion. We suggest using insulin secretion, determined from CGR, as an essential input for therapeutic decisions at the beginning or modification of diabetes treatment. Furthermore, we propose 3 practical steps to guide decisions in the subtype-specific therapy of diabetes mellitus. The first step consists of detecting insulin deficiency indicated by a low CGR with the need for immediate insulin therapy. The second step is related to high CGR and aims at lowering cardiovascular risk associated with diabetes. The third step is the consideration of a de-escalation of glucose-lowering therapy in individuals with mild diabetes subphenotypes.

Key words

insulin secretion - classification - subphenotype - C-peptide - treatment

Publication History

Received: 13 July 2020
Received: 12 August 2020

Accepted: 18 August 2020

Article published online:
18 September 2020

• References

• 1 Zheng SL, Roddick AJ, Aghar-Jaffar R. et al. Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes: a systematic review and meta-analysis. JAMA 2018; 319: 1580-1591.
• 2 Davies MJ, D'Alessio DA, Fradkin J. et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2018; 61: 2461-2498
• 3 Buse JB, Wexler DJ, Tsapas A. et al. 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2020; 63: 221-228
• 4 Cosentino F, Grant PJ, Aboyans V. et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2020; 41: 255-323.
• 5 Ahlqvist E, Storm P, Käräjämäki A. et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol 2018; 6: 361-369
• 6 Dennis JM, Shields BM, Henley WE. et al. Disease progression and treatment response in data-driven subgroups of type 2 diabetes compared with models based on simple clinical features: an analysis using clinical trial data. Lancet Diabetes Endocrinol 2019; 7: 442-451
• 7 Zaharia OP, Strassburger K, Strom A. et al. Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study. Lancet Diabetes Endocrinol 2019; 7: 684-694
• 8 Thomas NJ, Jones SE, Weedon MN. et al. Frequency and phenotype of type 1 diabetes in the first six decades of life: a cross-sectional, genetically stratified survival analysis from UK Biobank. Lancet Diabetes Endocrinol 2018; 6: 122-129
• 9 Thomas NJ, Lynam AL, Hill AV. et al. Type 1 diabetes defined by severe insulin deficiency occurs after 30 years of age and is commonly treated as type 2 diabetes. Diabetologia. 2019; 62: 1167-1172
• 10 Boeder S, Edelman SV. Sodium-glucose co-transporter inhibitors as adjunctive treatment to insulin in type 1 diabetes: A review of randomized controlled trials. Diabetes Obes Metab 2019; 21: 62-77 doi:10.1111/dom.13749
• 11 Hörber S, Achenbach P, Schleicher E. et al. Harmonization of immunoassays for biomarkers in diabetes mellitus. Biotechnol Adv 2020; 39: 107359.
• 12 Becht FS, Walther K, Martin E. et al. Fasting C-peptide and Related Parameters Characterizing Insulin Secretory Capacity for Correctly Classifying Diabetes Type and for Predicting Insulin Requirement in Patients with Type 2 Diabetes. Exp Clin Endocrinol Diabetes 2016; 124: 148-156
• 13 Herzberg-Schäfer SA, Staiger H, Heni M. et al. Evaluation of fasting state-/oral glucose tolerance test-derived measures of insulin release for the detection of genetically impaired β-cell function. PLoS One. 2010; 5: e14194
• 14 Schäfer SA, Tschritter O, Machicao F. et al. Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms. Diabetologia 2007; 50: 2443-2450
• 15 Schmid V, Wagner R, Sailer C. et al. Non-alcoholic fatty liver disease and impaired proinsulin conversion as newly identified predictors of the long-term non-response to a lifestyle intervention for diabetes prevention: results from the TULIP study. Diabetologia 2017; 60: 2341-2351
• 16 Bingley PJ. Clinical applications of diabetes antibody testing. J Clin Endocrinol Metab 2010; 95: 25-33. doi:10.1210/jc.2009-1365
• 17 Cahn A, Raz I, Kleinman Y. et al. Clinical assessment of individualized glycemic goals in patients with type 2 diabetes: Formulation of an algorithm based on a survey among leading worldwide diabetologists. Diabetes Care 2015; 38: 2293-2300.
• 18 Mol PGM, Thompson A, Heerspink HJL. et al. Precision medicine in diabetes and diabetic kidney disease: Regulatory considerations. Diabetes Obes Metab 2018; 20: 19-23